No Data
AVTX Avalo Therapeutics
Watchlist- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Avalo Therapeutics Company
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Revenue Breakdown
News
Avalo Therapeutics Q3 EPS $(0.11) Down From $0.34 YoY, Sales $236.00K Down From $14.95M YoY
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.11) per share. This is a 132.35 percent decrease over earnings of $0.34 per share from the same period last year. The company reporte
Earnings Flash (AVTX) AVALO THERAPEUTICS Reports Q3 Revenue $236,000
07:09 AM EST, 11/09/2023 (MT Newswires) -- Earnings Flash (AVTX) AVALO THERAPEUTICS Reports Q3 Revenue $236,000
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares rose 26.5% to $0.12 during Tuesday's pre-market session. The company's market cap stands at $22.5 million. LumiraDx (NASDAQ:LMDX) stock rose 22.88% to $0
OhNowGombie : Holy shit!
Clueless NoobOP OhNowGombie: i know, right?
OhNowGombie Clueless NoobOP: I saw a lotta sell orders piling up yesterday, but dang!!!